(Q36158732)

12 August 2017

1 reference

title

Glucagon as a target for the treatment of Type 2 diabetes (English)

1 reference

12 August 2017

1 reference

1 reference

Kyle W Sloop

1

1 reference

12 August 2017

M Dodson Michael

series ordinal

2

1 reference

12 August 2017

Julie S Moyers

series ordinal

3

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

Expert Opinion on Therapeutic Targets

12 August 2017

published in

1 reference

12 August 2017

volume

9

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

593-600

1 reference

Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake.

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Differential Processing of Proglucagon by the Subtilisin-like Prohormone Convertases PC2 and PC3 to Generate either Glucagon or Glucagon-like Peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Role of the prohormone convertase PC2 in the processing of proglucagon to glucagon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Glucagon replacement via micro-osmotic pump corrects hypoglycemia and alpha-cell hyperplasia in prohormone convertase 2 knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Abrogation of protein convertase 2 activity results in delayed islet cell differentiation and maturation, increased alpha-cell proliferation, and islet neogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Adrenaline stimulates glucagon secretion in pancreatic A-cells by increasing the Ca2+ current and the number of granules close to the L-type Ca2+ channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

In vivo and in vitro regulation of hepatic glucagon receptor mRNA concentration by glucose metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Glucagon receptors on human islet cells contribute to glucose competence of insulin release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Glucagon stimulates exocytosis in mouse and rat pancreatic alpha-cells by binding to glucagon receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Role of liver in pathophysiology of NIDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Development of potent truncated glucagon antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Human glucagon receptor antagonists based on alkylidene hydrazides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Generation of mice expressing the human glucagon receptor with a direct replacement vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Glycemic control in mice with targeted disruption of the glucagon receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

Evidence for a Major Role for Glucagon in Regulation of Plasma Glucose in Conscious, Nondiabetic, and Alloxan-Induced Diabetic Rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.593

21 January 2018

Identifiers

DOI

10.1517/14728222.9.3.593

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vutnkfuczfbzhhmmrjdtkp3p5a

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_vutnkfuczfbzhhmmrjdtkp3p5a

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vutnkfuczfbzhhmmrjdtkp3p5a

mapped directly with Wikidata item

30 July 2022

based on heuristic

https://api.fatcat.wiki/v0/release/vutnkfuczfbzhhmmrjdtkp3p5a

1 reference